In AD, a body of increasing evidence indicates that the inhibition of the AKT/mTOR signaling pathway may contribute to alleviating AD‐related cognitive impairment and pathological manifestations [26, 27]. This evidence concerns the gene AKT1 and Alzheimer disease.